Quick Overview: Interview with Christopher J. Moreau, CEO of Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Algernon Pharmaceuticals Phase 1 Dmt - Detailed Overview & Context

Interview with Christopher J. Moreau, CEO of Interview with CEO Christopher Moreau and host Cyndi Edwards regarding news about the next steps in

Photo Gallery

Algernon Pharmaceuticals subsidiary completes first dosing in Phase 1 clinical study of DMT
Algernon Pharmaceuticals gains approval for Phase 1 clinical study of DMT for treatment of stroke
Algernon Pharmaceuticals Phase 1 DMT stroke study will start in September of 2022
Algernon Pharmaceuticals completes manufacturing of Psychedelic Drug DMT for Phase 1 and 2 study
Algernon Pharmaceutical files for Clinical Trial and Ethics approval for Phase 1 DMT Stroke study
Market One - Algernon Pharmaceuticals - First Company to Investigate DMT as a Treatment for Stroke
Algernon Pharmaceuticals DMT Stroke Clinical Program
Algernon gets approval for groundbreaking phase 1 study of DMT for stroke
Algernon Pharmaceuticals looks to highly regarded UK company to conduct Phase 1 DMT stroke study
Algernon Pharmaceuticals Update - Manufacturing a Secure DMT Supply
Algernon Pharmaceuticals established Optimum Treatment Period for DMT
Algernon Pharmaceuticals (CSE:AGN) establishes optimum treatment period for DMT in neuron study
Sponsored
Sponsored
View Main Result
Sponsored
Sponsored